Today: 6 March 2026
Subscribe
Browse Category

Stock Market 13 November 2025

Stock Market Today, Nov. 13, 2025: Dow Slides as Disney Plunges and Tech Stocks Drop After Trump Ends Record Shutdown

Stock Market Today, Nov. 13, 2025: Dow Slides as Disney Plunges and Tech Stocks Drop After Trump Ends Record Shutdown

The Dow Jones retreated about 0.2% to 48,168 Thursday after closing above 48,000 for the first time. Wall Street pulled back as the U.S. government reopened following a 43-day shutdown, Disney shares plunged, and Big Tech faced renewed selling. The S&P 500 dropped 0.5%, while the Nasdaq fell 0.9%. Treasury yields and volatility rose as traders reassessed Fed rate-cut odds.
13 November 2025
·
John Hancock Group of Funds Adds Two Independent Trustees as Chicago’s John Hancock Prep Rallies Support for Thanksgiving ‘Harvest Havoc’ Tournament

John Hancock Group of Funds Adds Two Independent Trustees as Chicago’s John Hancock Prep Rallies Support for Thanksgiving ‘Harvest Havoc’ Tournament

The John Hancock Group of Funds appointed Christine L. Hurtsellers and Kenneth J. Phelan as independent trustees, expanding its board to 12 independent members. Separately in Chicago, John Hancock College Prep called for community support ahead of its first Thanksgiving basketball tournament. The organizations are unrelated and share only the John Hancock name.
13 November 2025
··
Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics shares rose about 22% after the FDA accepted its resubmitted Biologics License Application for ONS‑5010/LYTENAVA as a treatment for wet AMD, setting a PDUFA review date of December 31, 2025. The FDA classified the filing as a complete, Class 1 response, triggering a 60-day review. The move follows an August rejection over insufficient efficacy data. ONS‑5010/LYTENAVA is already approved in the EU and UK.
13 November 2025
··
Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine shares surged Thursday after the company received final approval to expand its FDA-regulated Phase 1/2a trial for Alcohol Use Disorder to Hadassah Medical Center in Jerusalem. The firm also filed for a registered direct offering of shares and pre-funded warrants, raising new capital but prompting dilution concerns among investors. The trial now includes sites at Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah.
13 November 2025
··
Manulife (MFC.TO) Hits Record High on Q3 Beat, India Mahindra JV and $350M Longevity Push

Manulife (MFC.TO) Hits Record High on Q3 Beat, India Mahindra JV and $350M Longevity Push

Manulife shares hit a record C$49.82 in Toronto, up as much as 3.3%, after the insurer beat Q3 estimates and announced a 50:50 life-insurance joint venture in India with Mahindra & Mahindra. Core earnings rose 10% to $2.04 billion, with core EPS up 16% to $1.16, both above analyst forecasts. Asia core earnings jumped 29%, while U.S. core earnings fell 20% on higher claims.
13 November 2025
·
Nebius (NBIS) Stock Slides After Q3 2025 Earnings: $3B Meta AI Deal, Microsoft Pact and CoreWeave Rivalry, Explained

Nebius (NBIS) Stock Slides After Q3 2025 Earnings: $3B Meta AI Deal, Microsoft Pact and CoreWeave Rivalry, Explained

Nebius shares fell about 6% to $88–$90 intraday Tuesday, extending a slide of over 30% from last month’s highs despite reporting 355% year-over-year revenue growth and a new $3 billion AI contract with Meta. Q3 revenue reached $146.1 million, but net loss widened to $119.6 million. The stock remains up more than fourfold this year. Rival CoreWeave also declined after cutting capital spending guidance.
13 November 2025
···
VisionSys AI (VSA) Crashes Nearly 78% After $12 Million Direct Offering as Shareholders Head Into High‑Stakes Vote

VisionSys AI (VSA) Crashes Nearly 78% After $12 Million Direct Offering as Shareholders Head Into High‑Stakes Vote

VisionSys AI Inc. shares plunged 77.7% to $0.29 on November 12 after announcing a $12 million registered direct offering of ADS and warrants, triggering heavy selling and social media attention. The deal allows institutional investors to buy 9.23 million ADS units at $1.30 each, with warrants exercisable for up to three ADSs per warrant, raising dilution concerns.
13 November 2025
··
DLocal (DLO) Stock Tumbles After Record Q3 2025 Earnings and New WhatsApp Remittance Push

DLocal (DLO) Stock Tumbles After Record Q3 2025 Earnings and New WhatsApp Remittance Push

DLocal shares fell about 9% to $13.50 in late-morning New York trading Thursday, erasing gains from a post-earnings rally after record Q3 results. Investors cited margin pressure and softer economics in key markets. The company also announced a stablecoin-funded WhatsApp remittance partnership with Félix, expanding its cross-border payments push in Latin America.
13 November 2025
···
TNL Mediagene (TNMG) Stock Explodes on Coupang Deal: What Today’s Partnership Means for Taiwan’s Content Commerce Boom – 13 November 2025

TNL Mediagene (TNMG) Stock Explodes on Coupang Deal: What Today’s Partnership Means for Taiwan’s Content Commerce Boom – 13 November 2025

TNL Mediagene announced a strategic partnership with Coupang targeting Taiwan’s content commerce and retail media market. TNMG shares surged 46% to $0.44 by mid-morning November 13, lifting its market cap to about $12 million. The alliance will integrate TNL’s media brands with Coupang’s e-commerce, using AI-driven ad solutions and first-party data.
13 November 2025
···
Gambling.com Group (GAMB) Stock Crashes After Record Q3 2025 Earnings and Guidance Cut

Gambling.com Group (GAMB) Stock Crashes After Record Q3 2025 Earnings and Guidance Cut

Gambling.com Group shares fell over 25% Thursday after reporting record Q3 2025 revenue of $38.98 million, up 21% year-over-year, but posting a net loss of $3.86 million versus a profit last year. The company cited search-traffic headwinds and a cautious outlook. By mid-morning, the stock traded near $5.08, down more than 70% from its 52-week high. Sports data services revenue surged 304% to $9.2 million.
13 November 2025
··
Rubico Inc. (RUBI) Stock Slides Again After $84 Million Fleet Refinancing — All the Key Updates for 13 November 2025

Rubico Inc. (RUBI) Stock Slides Again After $84 Million Fleet Refinancing — All the Key Updates for 13 November 2025

Rubico Inc. closed an $84 million sale-and-leaseback refinancing for its two Suezmax tankers, unlocking $10.4 million in cash. Shares fell 13.9% to $0.1999 Wednesday, near all-time lows, following a steep drop after a $7.5 million public offering earlier this month. Trading volume topped 95 million shares. Market capitalization now stands at about $0.6–0.7 million.
13 November 2025
·
Sonder Holdings (SOND) Nears Chapter 7 After Marriott Split: Stock & Bankruptcy Update for November 13, 2025

Sonder Holdings (SOND) Nears Chapter 7 After Marriott Split: Stock & Bankruptcy Update for November 13, 2025

Sonder Holdings is winding down operations and expects to file for Chapter 7 bankruptcy in the U.S., with insolvency proceedings abroad. Guests at its properties have reported being told to leave with little notice. SOND stock traded around $0.17 on Nov. 13, near record lows, after swinging between $0.20 and $0.37 on heavy volume. The company’s market cap has fallen to about $3 million from billions at its 2022 debut.
13 November 2025
··
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals announced partnerships with Eli Lilly and Novo Nordisk to offer official access to Zepbound and Wegovy through new telehealth programs, MangoRx Direct and PeachesRx Direct. Membership costs $99 per month, with GLP‑1 drugs starting at $499 monthly, no insurance required. MGRX shares jumped over 25% pre-market before retreating. The company recently settled a lawsuit with Lilly and reported a $10.3 million net loss.
13 November 2025
····
Stratasys (SSYS) Q3 2025 Earnings: Revenue Slips, Cash Flow Strengthens as 3D Printing Leader Reaffirms 2025 Outlook

Stratasys (SSYS) Q3 2025 Earnings: Revenue Slips, Cash Flow Strengthens as 3D Printing Leader Reaffirms 2025 Outlook

Stratasys reported Q3 2025 revenue of $137 million, down 2.2% year over year, and a GAAP net loss of $55.6 million, more than double last year’s loss due to a $33.9 million non-cash impairment. Cash from operations improved to $6.9 million, with $255 million in cash and no debt. Shares rose about 7% intraday as investors focused on positive cash flow. Full-year guidance was reaffirmed.
13 November 2025
··
Bitfarms (BITF) Stock Slips After Q3 2025 Miss as AI & HPC Pivot Kicks Into High Gear

Bitfarms (BITF) Stock Slips After Q3 2025 Miss as AI & HPC Pivot Kicks Into High Gear

Bitfarms reported Q3 2025 revenue of $69 million, up 156% year-on-year but missing the $83.1 million consensus. Net loss widened to $46 million, or -$0.08 per share, versus an expected -$0.02. The company unveiled plans to convert its Washington facility for Nvidia AI chips by December 2026. Shares fell 13% pre-market and traded down 6% intraday to $3.17.
13 November 2025
·····
Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio shares plunged nearly 80% to around $6.60 in pre-market trading Thursday after the company reported mixed early data from its lead RNA-editing program, KRRO‑110, and announced layoffs, a pipeline shift, and a year-long pause in its Novo Nordisk partnership. The Phase 1/2a trial showed KRRO‑110 increased AAT protein but did not reach protective levels.
13 November 2025
··
Firefly Aerospace (FLY) Stock Jumps on Q3 2025 Earnings Beat, Raised Guidance and Alpha Rocket Comeback Plan

Firefly Aerospace (FLY) Stock Jumps on Q3 2025 Earnings Beat, Raised Guidance and Alpha Rocket Comeback Plan

Firefly Aerospace reported Q3 2025 revenue of $30.8 million, nearly double the previous quarter, and raised its full-year outlook. Shares surged up to 22% pre-market after the results, then fell back to $18.31, near record lows. The company faces multiple shareholder lawsuits tied to its August IPO and a September rocket test failure. Net loss widened to $133.4 million from $40.8 million a year earlier.
13 November 2025
···
NICE Ltd. (NICE) Stock Pops as Q3 2025 Earnings Showcase AI‑Driven Cloud Growth and Raised Revenue Guidance

NICE Ltd. (NICE) Stock Pops as Q3 2025 Earnings Showcase AI‑Driven Cloud Growth and Raised Revenue Guidance

NICE Ltd. reported Q3 2025 revenue of $732 million, up 6% and above analyst expectations, with cloud revenue rising 13% to $562.9 million. GAAP net income reached $144.9 million, up 20% from a year earlier. The company raised its full-year non-GAAP revenue outlook but trimmed EPS guidance. Shares rose 6–9% in pre-market trading after results.
13 November 2025
····
1 … 1,186 1,187 1,188 1,189 1,190 … 1,335
Go toTop